Abstract
VGF is a propeptide of 617 amino acids expressed throughout the central and the peripheral nervous system. VGF and peptides derived from its processing have been found in dense core vesicles and are released from neuronal and neuroendocrine cells via the regulated secretory pathway. Among VGF-derived neuropeptides, TLQP-21 (VGF556-576) has raised a huge interest and is one of most studied. TLQP-21 is a multifunctional neuropeptide involved in the control of several physiological functions, potentially including energy homeostasis, pain modulation, stress responsiveness and reproduction. Although little information is available about its receptor and the intracellular mechanisms mediating its biological effects, recent reports suggest that TLQP-21 may bind to the complement receptors C3aR1 and/or gC1qR. The first aim of this study was to ascertain the existence and nature of TLQP-21 binding sites in CHO cells. Secondly, we endeavored to characterize the ligand binding to these sites by using a small panel of VGF-derived peptides. And finally, we investigated the influence of TLQP-21 on selected intracellular signaling pathways. We report that CHO cells express a single class of saturable and specific binding sites for TLQP-21 with an affinity and capacity of Kd = 0.55 ± 0.05 × 10-9 M and Bmax = 81.7 ± 3.9 fmol/mg protein, respectively. Among the many bioactive products derived from the C-terminal region of VGF that we tested, TLQP-21 was the most potent in stimulating intracellular calcium mobilization in CHO cells; this effect is primarily due to its C-terminal fragment (HFHH-10). TLQP-21 induced rapid and transient dephosphorylation of phospholipase Cγ1 and phospholipase A2. Generation of IP3 and diacylglycerol was crucial for TLQP-21 bioactivity. In conclusion, our results suggest that the receptor stimulated by TLQP-21 belongs to the family of the Gq-coupled receptors, and its activation first increases membrane-lipid derived second messengers which thereby induce the mobilization of Ca2+ from the endoplasmic reticulum followed by a slower store-operated Ca2+ entry from outside the cell.
Introduction
The vgf gene, originally identified as a nerve growth factor responsive gene in PC12 cells (), has a tissue-specific pattern of expression limited to specific neurons and to specific endocrine cells (; ). In rodents, the vgf gene encodes a 617 amino acid protein which is included in the extended granin family and is named secretogranin VII (). Secretogranin VII itself is proteolytically processed to yield more than ten different bioactive peptides (). In the rat brain, VGF is expressed in areas involved in the regulation of feeding, reproduction, stress responsiveness and general homeostasis (; ; ), and VGF-derived peptides have been found significantly decreased in some neurodegenerative diseases (; ; ). VGF immunoreactivity was, as well, reported in gonadotroph and lactotroph cells in the rat anterior pituitary ().
GRAPHICAL ABSTRACT
Among several bioactive peptides derived from VGF, TLQP-21 (VGF556-576) is a 21 amino acid peptide which has been immunopurified from brain tissues (). Despite many efforts to characterize the physiological effects of TLQP-21, little is known about its molecular targets. Nonetheless, adipocytes express a high affinity binding site for TLQP-21 and in these cells TLQP-21 stimulates a pro-lipolytic effect (). Moreover, we have recently demonstrated TLQP-21 binding sites on CHO cells through the use of Atomic Force Microscopy (). Interestingly, the rat ovary express high levels of TLQP-21, which has been proposed to affect female reproduction by modulating pituitary LH release (; ) The statistical distribution of the attractive force between TLQP-21 and its binding site is indicative of a single class of binding sites. This presence of a TLQP-21 binding site in these cells is consistent with their unique dose- and time-dependent increases of intracellular calcium (Ca2+) mobilization in response to TLQP-21 (). TLQP-21 stimulation of intracellular Ca2+ was concentration-dependent, whereas LRPS-21 (a scrambled control peptide that contains the same amino acids residues of TLQP-21 but rearranged in a random order to prevent homology with other published proteins) did not stimulate Ca2+ increases in CHO cells, confirming the specificity of TLQP-21 effects. Furthermore, N38 cells, which do not respond to TLQP-21, do not express binding sites for TLQP-21 in the Atomic Force Microscopy measurements ().
It has recently been proposed that the complement component 3a receptor 1 (C3aR1) mediates TLQP-21 signaling in CHO cells, and that TLQP-21 could be a natural agonist of this receptor (). Noteworthy, it has been reported that the stimulation of CHO cells with TLQP-21 did not induce any measurable intracellular Ca2+ increase unless cells were subjected to a strong priming with 100 μM ATP (). Other authors have also reported that in rat macrophages TLQP-21 binds specifically to the complement component C1q receptor (gC1qR) (). Interestingly, gC1qR and C3aR1 are receptors for complement protein and it is possible that TLQP-21 interacts with both receptors; however, which receptor mediates the effects of TLQP-21 is still object of debate.
Since TLQP-21 is emerging as a novel target for obesity-associated disorders (; ), diabetes (), neuropathic pain (; ) and other human pathologies (), the purpose of this study was to better characterize the binding site for TLQP-21 in CHO cells, investigating its binding characteristics and the intracellular pathways activated by the peptide-receptor interaction. The data presented here clearly indicate that TLQP-21 binds to a single class of receptors, probably belonging to the family of the Gq-coupled receptors, and stimulates intracellular Ca2+ release primarily from the endoplasmic reticulum (ER).
Materials and Methods
Chemicals
TLQP-21 (TLQPPASSRRRHFHHALPPAR), YATL-23 (YATLQ PPASSRRHFHHALPPAR), TLQP-62 (TLQPPASSRRRHFHHA LPPARHHPDLEAQARRAQEEADAEERRLQEQEELEN-YIEH VLLHRP), TLQP-8 (TLQPPASS), HFHH-10 (HFHHALPP AR), HHPD-41 (HHPDLEAQARRAQEEADAEERRLQEQEELE NYIEHVLLHRP), and LRPS-21 (LRPSHTRPAHQSFARP LHRPA) have been synthesized by us using conventional solid phase synthesis.
Cyclosporine A (CsA), thapsigargin (TG), U73122, 2-Aminoethyl diphenylborinate (2-APB), SKF-96365, YM-58483, and EGTA were purchased from Sigma–Aldrich (St Louis, MO, USA). Unless otherwise specified, all other reagents were from Sigma–Aldrich.
Cell Cultures
CHO cells were cultured in HAM’S F12 medium supplemented with 10% heat-inactivated foetal bovine serum (FBS), 100 IU/ml penicillin, 100 μg/ml streptomycin, and 2 mM L-glutamine (all Euroclone, Pero, Italy) under standard cell culture conditions (at 37°C, in 5% CO2).
Intracellular Ca2+ Mobilization Assay
CHO cells were plated at 20.000 cells/well into black walled, clear bottom 96-well plate (Corning, Germany) and cultured one day up to 80–90% of confluence. Prior to assay, cells were incubated in dark conditions with 100 μl of Hank’s Balanced Salt Solution (HBSS) containing 20 mM HEPES, 2.5 mM probenecid and 4.5 μM FLUO-4 NW (Molecular Probes, Eugene, OR, USA) at 37°C and 5% CO2 for 45 min. Fluorescence emissions were measured with the multilabel spectrophotometer VICTOR3 (Perkin Elmer, MA, USA) at 485/535 nm (excitation/emission filters) every 0.5 s for the 20 s preceding and the 60 s following the stimulation. TLQP-21, TLQP-62, TLQP-8, HHPD-41, HFHH-10, and LRPS-21 were diluted in HBSS solution and injected into the wells by an automated injector system. The nature of Ca2+ stores involved in TLQP-21 action was investigated preincubating cells with TG (2 μM, 20 min), an inhibitor of the Ca2+-ATPase pump responsible for sequestering Ca2+ in the ER (), or CsA (2 μM, 15 min), an inhibitor of the mitochondrial permeability transition pore (PTP) (). To ascertain whether phospholipase C (PLC) and inositol trisphosphate receptors (IP3R) were involved in TLQP-21 mechanism of action, cells were incubated with a specific PLC inhibitor (U73122, 10 μM for 10 min) and a IP3R antagonist (2-APB, 75 μM for 15 min) before the injection of TLQP-21 (; ). Depletion of Ca2+ from the ER leads to Ca2+ entry from outside the cell by activation of Store-Operated Channels (SOCs). Again, to assess the involvement of this pathway, CHO cells were incubated with selective antagonists of this pathway (SKF-96365 and YM-58483 10 μM for 20 min, EGTA 1 mM for 30 min) before the injection of TLQP-21 (; ).
TLQP-21 Binding Assay
Binding of TLQP-21 to crude membranes (30,000 × g pellet) obtained from CHO cells was carried out using [125I]-YATL-23 as ligand. YATL-23 was radioiodinated (specific activity, 2000 Ci/mmol) using the lactoperoxidase method (; ) by Perkin Elmer (Milan, Italy) and purified by reverse phase high-performance liquid chromatography. For the single point binding assay, cell membranes (corresponding to 100 μg membrane protein) were incubated in triplicate at 23°C, unless otherwise noted, for 4 h under constant shaking with 0.5 nM [125I]-YATL-23 in a final volume of 0.5 ml assay buffer (50 mM Tris, 2.5 mM EGTA, 0.002% bacitracin, 0.1% bovine serum albumin, titrated to a final pH of 7.4 with HCl). Non-specific binding was measured in parallel incubations with 1 μM unlabelled YATL-23 to displace the radioligand. Similar results were obtained using TLQP-21 to displace the radioligand. The binding reaction was terminated by the addition of ice-cold assay buffer, followed by rapid filtration through Whatman GF/B filters as previously reported () and the radioactivity bound to membranes was measured by a Packard auto-γ-counter. Specific binding-values were calculated as the difference obtained subtracting non-specific from total binding. Specific binding was expressed as a percentage of the total radioactivity added. For saturation binding studies, cell membranes were incubated with various concentrations of the radioligand (0.03–4 nM). Competition studies were performed by incubating cell membranes (150 μg/tube) with 1 nM [125I]-YATL-23 with or without various concentrations (from 10 pM to 0.1 μM) of unlabelled YATL-23, TLQP-21, or LRPS-21. Data were plotted and curves fit using the GraphPad Prism software version 4 (GraphPad Software, San Diego, CA, USA) assuming that the binding was due to a single class of binding sites, thus allowing determination of the maximum binding capacity (Bmax), dissociation constant (Kd), Hill slope and concentration of the competitor causing 50% inhibition (IC50) of specific radioligand binding.
Phosphorylation of Cellular Kinases
CHO cells were plated 24 h before time course experiments in 35 mm dishes at 70% confluence. After three washes with medium w/o serum, cells were serum-starved for 1 h. Time course experiments were performed and after quick removal of the medium the reaction was stopped by placing the dish on ice and adding 100 μl of ice-cold lysis buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 10 mM EDTA) containing a protease inhibitor cocktail and PhosphoStop inhibitor cocktail (Roche Diagnostic, Mannheim, Germany).
Cells were stored at –80°C until further processing. Cells were harvested and equivalent amounts of cell extracts (corresponding to approximately 200.000 cells) were run on NuPAGE precast 4–12% gradient gels (Invitrogen, USA) and transferred to a polyvinylidene difluoride (PVDF) membrane (Amersham). After staining with Ponceau S to verify uniformity of protein load/transfer, membranes were analyzed for immunoreactivity. Incubation with primary antibodies (anti-phospho-AMPK (Thr172); anti-phospho-AKT (Ser473); anti-phospho-ERK1/2 (Thr202/Tyr204); anti-phospho-PKC (Ser660); anti-phospho-PLA2 (Ser505); anti-phospho-JNK (Ser63); and anti-phospho-PLCγ1 (Tyr783) rabbit polyclonal antibodies; Cell Signaling Technology, Danvers, MA, USA) at 1:1.000 dilution was performed overnight at 4°C (). Incubation with peroxidase-coupled secondary antibodies (Amersham, Arlington Heights, IL, USA; now GE; 1:5.000) was performed for 1 h at room temperature. Immunoreactivity was developed by enhanced chemiluminescence (ECL system; Amersham GE Healthcare, UK). Two parallel gels were run for each experiment and with probes for different anti-phosphorylated protein antibodies as indicated, avoiding stripping protocols. The gels were normalized with anti-β-actin monoclonal antibodies (Sigma). β-actin was chosen since we have previously observed that its levels remained stable in time, wherease those of α-tubulin decreased over time ().
Statistical Analysis
Values are expressed as mean ± SEM. The statistical significance of differences between groups was evaluated with Tukey–Kramer’s t-test for multiple comparisons, preceded by the analysis of variance (ANOVA). Where appropriate, F-values and degrees of freedom (DF) are indicated in the legend of figures. A P-value of less than 0.05 was considered significant.
Results
TLQP-21 Stimulates Intracellular Ca2+ Levels in CHO Cells
CHO cells were incubated in vitro with increasing concentrations (1 nM–10 μM) of TLQP-21. TLQP-21 (0.1 μM–10 μM) evoked acute and significant increases (P < 0.05) in intracellular Ca2+ levels in CHO cells (Figure 1A); by comparison, LRPS-21 tested at the concentration interval of 1 nM–10 μM did not stimulate Ca2+ levels in CHO cells (Figure 1A) thereby confirming the specificity of TLQP-21 action.
FIGURE 1
In the next series of experiments, we investigated whether CHO cells could respond to repeated TLQP-21 stimulations given at 5 min intervals from each other. Levels of free intracellular Ca2+ increased sharply upon the first challenge with 10 μM TLQP-21, whereas 5 min later a second application of 10 μM TLQP-21 induced only a blunted increase in cell fluorescence; no effects were observed when 5 min later 10 μM TLQP-21 was applied a third time (Figure 1B). A final challenge with 10 μM ATP to check for cell viability was not affected (data not shown).
Calcium Mobilizing Effects of VGF-Derived Peptides
To gain further insight into the biological activity of VGF-derived peptides, we stimulated CHO cells with different peptides derived from the C-terminal region of VGF (Table 1). Natural processing of TLQP-62 by prohormone convertases yields TLQP-21 and HHPD-41 (Table 1). The 1 μM concentration has been chosen to compare the effects of TLQP-62 and its fragments on intracellular Ca2+ levels since this concentration was close to the EC50 of TLQP-21 and could have allowed to measure whether a test compound was less or more active than TLQP-21. At concentrations as large as 1 μM TLQP-62 failed to stimulate any significant increase in intracellular Ca2+ levels (Figure 2). Similarly, HHPD-41 was also ineffective, whereas TLQP-21 significantly stimulated intracellular calcium mobilization (Figure 2). TLQP-21 itself is a substrate for prohormone convertases to yield TLQP-8 (8 amino acids at the N-terminal of TLQP-21) and HFHH-10 (10 amino acids at the C-terminal of TLQP-21). HFHH-10 effectively stimulated an intracellular Ca2+ increase in CHO cells; by comparison, TLQP-8 at 1 μM induced only a slight and non-significant increase in intracellular Ca2+. These results strongly suggest that the C-terminal region of TLQP-21 is the sequence primarily involved in the stimulation of its receptor on CHO cells (Figure 2).
Table 1
 |
Aminoacidic sequence of peptides of the C-terminal region of VGF.
FIGURE 2
TLQP-21 Binding Analysis in CHO Cells
The addition of Tyr-Ala (YA) amino acidic residues to TLQP-21 resulted in a peptide (YATL-23) with the same in vitro biological activity of TLQP-21 in CHO cells (data not shown).
Given the evidence of intracellular Ca2+ mobilization induced by TLQP-21 in CHO cells, we investigated the presence of specific TLQP-21 binding sites on CHO cell membranes by radioreceptor assay using [125I]-YATL-23 as a ligand. The specific binding of [125I]-YATL-23 to cell membranes varied with both incubation time and temperature. Specific binding increased with the duration of incubation and was greater at 23°C when compared to 4°C after reaching equilibrium at 4 h (Figure 3A). A study of specific binding as a function of membrane protein concentration indicated that the binding was proportional to protein content up to at least 100 μg/tube (Figure 3B). Specific binding of [125I]-YATL-23 to cell membranes occurred over a relatively wide range of pH. The maximal binding was observed at pH 7.4 and declined to half-maximal value at pH 5.0 and 9.0 (Figure 3C). Therefore, all subsequent incubations were carried out at pH 7.4 for 4 h at 23°C with 100 μg membrane protein. Brief exposure of CHO cell membranes to high temperature (100°C × 1 min) or enzymes that disrupt protein structure such as trypsin (50 μg/ml × 5 min) caused the loss of the specific binding of [125I]-YATL-23, suggesting that protein integrity is functionally important in the binding site (Figure 3D).
FIGURE 3
Experiments using various concentrations of [125I]-YATL-23 indicated the presence of a saturable and specific binding associated with minor low non-specific binding (Figure 4A). Scatchard transformation of the specific binding data (Figure 4B) yielded a linear Scatchard plot with Hill slope close to 1 (Figure 4C), indicating the existence of a single class of binding sites. The calculated Kd and Bmax values (means ± SEM of three independent experiments) were 0.55 ± 0.05 × 10-9 M and 81.7 ± 3.9 fmol/mg protein, respectively, and the Hill slope was 1.07 ± 0.1.
FIGURE 4
Unlabelled YATL-23 and TLQP-21 competed in a concentration-dependent manner with [125I]-YATL-23 for binding sites in CHO membranes (Figure 5). The IC50 values, calculated according a one-site binding model (means ± SEM of three independent experiments), were 1.2 ± 0.06 × 10-9 M for YATL-23 and 0.98 ± 0.06 × 10-9 M for TLQP-21. The results of these competition binding studies also revealed that the binding of [125I]-YATL-23 to CHO membranes was specific and was not inhibited by LRPS-21, the scrambled peptide made using the same amino acidic residues of TLQP-21 (Figure 5). These findings provide evidence that CHO cells contain significant amounts of TLQP-21 binding sites showing typical features of ligand-receptor interaction.
FIGURE 5
Intracellular Transduction Mechanisms Activated by TLQP-21
It is known that Ca2+ stores, such as ER and mitochondria, dynamically participate in generation of cytoplasmic Ca2+ signals (). We therefore studied the possible implication of these intracellular organelles in the increase of intracellular Ca2+ levels induced by TLQP-21. The involvement of the ER was investigated using TG, which inhibits the Ca2+-ATPase pump responsible for sequestering Ca2+ in the ER and depletes the store by irreversibly preventing its refilling. As shown in Figure 6A, TG reduced the TLQP-21-mediated increase of intracellular Ca2+, causing a 56% reduction after 20 min preincubation time. To rule out the possibility that Ca2+ release from the mitochondria could also be involved, we evaluated the effect of TLQP-21 in the presence of CsA, an inhibitor of the mitochondrial PTP (). The incubation of CHO cells with 2 μM CsA did not modify the basal levels of intracellular Ca2+ and a subsequent stimulation with 1 μM TLQP-21 induced a significant increase in intracellular Ca2+ levels (Figure 6A). These results indicate that TLQP-21 stimulated Ca2+ release primarily from the ER store, whereas release of Ca2+ from the mitochondria appeared not involved in this mechanism of action.
FIGURE 6
In many cellular systems, PLC activation and subsequent IP3 production is the transduction pathway regulating the release of Ca2+ from ER. U73122 is an aminosteroid that is reported to act as a specific inhibitor of PLC () and it is widely used as a quick test for the involvement of PLC in a signaling pathway. To test whether TLQP-21 induces Ca2+ mobilization through a PLC-dependent mechanism, CHO cells were incubated for 10 min with 10μM U73122. Results demonstrate that U73122 induced a dramatic reduction, about 82%, of TLQP-21 stimulation of intracellular Ca2+ mobilization (Figure 6B). As a further confirmation, CHO cells were pre-incubated for 15 min with 75 μM 2-APB, which rapidly inhibits IP3R-mediated Ca2+ release. Treatment with 2-APB strongly affect TLQP-21 activity, causing a decrement of intracellular Ca2+ mobilization of about 79% (Figure 6B). As previously reported, depletion of Ca2+ from the ER causes the activation of stromal interaction molecule (STIM) proteins that, translocating into junctions formed between the ER and the plasma membrane (PM), activate the highly calcium-selective Orai channels to homeostatically balance intracellular calcium (). To assess the role of this pathway, CHO cells were pretreated with a STIM-mediated Ca2+ inhibitor (SKF-96365), an inhibitor of Orai channels (YM-58483) or an extracellular Ca2+ chelator (EGTA) before stimulation with 1 μM TLQP-21. We observed a statistically significant decrement in TLQP-21-mediated intracellular Ca2+ mobilization (Figure 6C), of about 36, 27, and 45% after treatment with SKF-96365, YM-58483, and EGTA, respectively.
Next, we measured the effects of TLQP-21 treatment on phosphorylation of intracellular signaling effectors. After 1 h of serum starvation, cells were exposed to 10 μM TLQP-21 for 0–30 min (Figure 7). The 10 μM concentration was chosen because it elicited a stimulation near to maximal on intracellular Ca2+ mobilization (Figure 1). TLQP-21 induced a prompt increase of phospho-AKT (1–5 min) (Figure 7A) that remained significantly higher than basal until 15 min after stimulation (Figure 7A). A rapid and transient dephosphorylation of phospho-AMPK and phospho-PLCγ1 occurred between 1 and 10 min after stimulation with TLQP-21(Figures 7B,C). A similar trend was seen also for phospho-PLA2, but dephosphorylation reached statistical significance only at 2 min (Figure 7D). Interestingly, PKC phosphorylation increased after 2 min and lasted until 15 min from stimulation with TLQP-21 (Figure 7D). ERK1/2 phosphorylation increased significantly at 2 min, reached a peak at 5 min and thereafter returned to basal (Figure 7F). No effects were induced on phospho-JNK levels (data not shown). A possible limitation of these determinations is that sample loading was normalized using the corresponding β-actin levels and not the levels of the unphosphorilated protein.
FIGURE 7
Discussion
The molecular mechanisms of TLQP-21 action at the cellular level are still an object of debate, although this peptide could represent an important target to counteract human disorders, including obesity and diabetes. Our results demonstrate that TLQP-21 is a robust extracellular signal capable of promoting a Ca2+-mediated transduction signal in CHO cells. TLQP-21 is one of many bioactive products derived from post-translational cleavage of the C-terminal region of VGF, a propeptide that could be involved in psychiatric, neurologic and metabolic disorders (; ; ; ). Although TLQP-21 has been implicated in the regulation of energy balance, nociception, gastric function, and several other physiologic functions, its binding site and mechanisms of action remain largely unknown (; ; ). We have investigated the ability of some VGF-derived peptides to induce intracellular Ca2+ mobilization in CHO cells. Our results show that: (i) TLQP-21 stimulates a sharp increase in free intracellular Ca2+ levels; (ii) on this pathway it is more active than other VGF-derived peptides; and (iii) its C-terminal fragment, that corresponds to HFHH-10 peptide, is the region primarily involved in the process of stimulating intracellular Ca2+ mobilization. These results are consistent with those indicating that the “hot spots” for TLQP-21 activity are localized in its C-terminal region (). The N-terminal region of the peptide appears more tolerant to modifications, since the introduction of Tyr-Ala (YA) amino acidic residues (YATL-23) did not change the activity on intracellular Ca2+ mobilization and the ability of the peptide to bind the receptor. However, the N-terminal region of TLQP-21, corresponding to the sequence of TLQP-8, is apparently devoid of any activity on intracellular Ca2+ mobilization. Interestingly, molecular dynamics simulations have revealed that TLQP-21 is characterized by a highly flexible nature that fluctuates between many conformations, spanning from a long helical to a more compact form (). Another factor adding complexity to the interpretation of the ability of VGF-derived fragments to activate their receptor is the demonstration that TLQP-21 undergoes a folding-upon-binding transition upon receptor binding (). Further studies are needed to understand whether HFHH-10 satisfies the random coil to helix transitions needed for activating G-protein coupled receptors ().
The results that we have obtained in this research clearly demonstrated that TLQP-21 interacts with a single class of binding site expressed on CHO cell membranes, further confirming those observations that we have previously reported using Atomic Force Microscopy (). It is interesting that the membranes of CHO cells contain significant amounts of TLQP-21 binding sites and this cell line can be a useful in vitro model to study TLQP-21 mechanisms of action. In our setting, TLQP-21 efficiently stimulated intracellular calcium levels in CHO cells without the need of ATP priming previously reported (). Ca2+ is a highly versatile second messenger involved in a variety of intracellular signaling pathways, including gene regulation, proliferation and cell death. Repeated exposure to TLQP-21 resulted in a reduced response, probably indicating a decrease in number of receptors available or a decreased activity of intracellular signaling pathways involved. Interestingly, TLQP-21 induced a specific desensitization to subsequent TLQP-21 treatments, but not to ATP, and these data are consistent with those reported in rat primary macrophages and cerebellar granule cells (; ).
We have also shown that TLQP-21 stimulation induced an increase of cytoplasmic Ca2+ levels that was determined by release of Ca2+ from intracellular stores. In particular, our studies indicate that in CHO cells Ca2+ is released mainly from the ER stores, as demonstrated by the treatment with TG, a Ca2+-ATPase pump inhibitor that depletes the ER store by preventing its refilling (), whereas Ca2+ release from the mitochondria did not appear involved. Our results also indicate that Ca2+ mobilization stimulated by TLQP-21 is triggered by the activation of PLC, since pretreatment of the cells with U73122, a known PLC inhibitor, induced a significant reduction of Ca2+ mobilization. Western blotting determinations indicated that TLQP-21 up-regulated the phosphorylation levels of ERK1/2, PKC and AKT in CHO cells. These kinases are activated by the dual phosphorylation of neighboring threonine and tyrosine residues in response to extracellular stimuli () Furthermore, our results show that TLQP-21 induced a rapid and transient dephosphorylation of AMPK, PLCγ1, and PLA2, whereas the phosphorylation state of JNK was not altered. The intricate balance of phosphorylation by kinases and dephosphorylation by phosphatases is essential for maintaining signal transduction networks in cells (). The rapid increase in the mobilization of intracellular Ca2+ is at least in part dependent on the PLCγ family of proteins, including PLCγ1 and PLCγ2 (). It is possible that the dephosphorylation of PLCγ1 that we have observed could be involved in the mechanisms by which TLQP-21 induced a clear desensitization to subsequent TLQP-21 treatments. These results suggest that the receptor stimulated by TLQP-21 should belong to the family of the Gq-coupled receptors. It is widely accepted that the IP3R on the ER are an essential link between PLC activation and initiation of Ca2+ release from the ER. We have shown that pretreating the CHO cells with 2-APB, an IP3Rs antagonist, the release of Ca2+ induced by TLQP-21 was heavily reduced, further confirming that the binding of TLQP-21 with its receptor activates the PLC pathway. Reportedly, rapid Ca2+ depletion from the ER activates slower Ca2+ entry from outside the cell (). STIM and Orai proteins are required for the store-operated Ca2+ entry process (; ). Consistently, we have found an inhibition of TLQP-21-mediated Ca2+ release following treatment with SKF-96365 and YM-58483, two specific STIM- and Orai-inhibitors, respectively. PLC activation by TLQP-21 is followed by an increase of PKC phosphorylation and, afterwards, ERK1/2 phosphorylation.
Given the previous identification of two putative receptors for TLQP-21, the C3aR1 in CHO and RAW264.7 cells, and the gC1qR in rat brain membranes, primary microglia, macrophages, and DRG neurons (; ), we have attempted its pharmacological characterization in CHO cells. We have also previously demonstrated the existence of a high-affinity binding site for TLQP-21 in white and brown adipocyte membranes, and adrenals, whose exact nature remains still unknown (). CHO cells could be a useful in vitro model to study the interaction of VGF-derived peptides with a putative specific binding site, but the possibility that different binding sites could be expressed by other cell systems cannot be ruled out. Understanding the mechanism of action of TLQP-21 could be of great relevance since this neuropeptide is purported to play important roles in the central nervous system and peripheral tissues.
Conclusion
Our results suggest that TLQP-21 effects in CHO cells could be mediated by a Gq-coupled receptor that quickly activates PLCβ, that produces DAG and IP3 as second messengers. DAG activates PKC that, in turn, stimulates ERK1/2 phosphorylation. On the other hand, by binding IP3R on the ER, IP3 stimulates a sharp increase of intracellular Ca2+ levels and the subsequent Ca2+ entry from outside the cell through STIM-Orai interaction (see Graphical abstract). The CHO cell line can be proposed as a useful model for developing new synthetic agonists and antagonists of TLQP-21 receptor, which could help a better understanding of the physiologic and pathological role of VGF-derived peptides.
Statements
Ethics statement
The study was made in vitro using cell lines only. No experiments were performed on animals or involved human beings. Approval from the local Ethic Committee or other regulatory agencies was not required.
Author contributions
AT, RP, VL, and RO supervised the entire project, designed research, and wrote the paper. GB and IR conceived and designed the experiments, interpreted and analyzed data, supervised all the experimental procedure. LM, LR, EB, PP, CG, GM, J-AF, PV, AB, and JM conceived and designed the experiments, performed research, interpreted, and analyzed data. AT, RO, and VL analyzed data and critically revised the manuscript.
Funding
This work was supported by Fondo di Ateneo per la Ricerca of the University of Milano-Bicocca [FAR to AT and VL].
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The reviewer JH and handling Editor declared their shared affiliation, and the handling Editor states that the process nevertheless met the standards of a fair and objective review.
References
1
AguilarE.PinedaR.GaytanF.Sanchez-GarridoM. A.RomeroM.Romero-RuizA.et al (2013). Characterization of the reproductive effects of the Vgf-derived peptide TLQP-21 in female rats: in vivo and in vitro studies.Neuroendocrinology9838–50. 10.1159/000350323
2
BarfordD.DasA. K.EgloffM. P. (1998). The structure and mechanism of protein phosphatases: insights into catalysis and regulation.Annu. Rev. Biophys. Biomol. Struct.27133–164. 10.1146/annurev.biophys.27.1.133
3
BartolomucciA.La CorteG.PossentiR.LocatelliV.RigamontiA. E.TorselloA.et al (2006). TLQP-21, a VGF-derived peptide, increases energy expenditure and prevents the early phase of diet-induced obesity.Proc. Natl. Acad. Sci. U.S.A.10314584–14589. 10.1073/pnas.0606102103
4
BartolomucciA.PossentiR.MahataS. K.Fischer-ColbrieR.LohY. P.SaltonS. R. (2011). The extended granin family: structure, function, and biomedical implications.Endocr. Rev.32755–797. 10.1210/er.2010-0027
5
BleasdaleJ. E.ThakurN. R.GrembanR. S.BundyG. L.FitzpatrickF. A.SmithR. J.et al (1990). Selective inhibition of receptor-coupled phospholipase C-dependent processes in human platelets and polymorphonuclear neutrophils.J. Pharmacol. Exp. Ther.255756–768.
6
BusseS.BernsteinH. G.BusseM.BielauH.BrischR.MawrinC.et al (2012). Reduced density of hypothalamic VGF-immunoreactive neurons in schizophrenia: a potential link to impaired growth factor signaling and energy homeostasis.Eur. Arch. Psychiatry Clin. Neurosci.262365–374. 10.1007/s00406-011-0282-7
7
CarretteO.DemalteI.ScherlA.YalkinogluO.CorthalsG.BurkhardP.et al (2003). A panel of cerebrospinal fluid potential biomarkers for the diagnosis of Alzheimer’s disease.Proteomics31486–1494. 10.1002/pmic.200300470
8
CassinaV.TorselloA.TempestiniA.SalernoD.BrogioliD.TamiazzoL.et al (2013). Biophysical characterization of a binding site for TLQP-21, a naturally occurring peptide which induces resistance to obesity.Biochim. Biophys. Acta1828455–460. 10.1016/j.bbamem.2012.10.023
9
CeroC.VostrikovV. V.VerardiR.SeveriniC.GopinathT.BraunP. D.et al (2014). The TLQP-21 peptide activates the G-protein-coupled receptor C3aR1 via a folding-upon-binding mechanism.Structure221744–1753. 10.1016/j.str.2014.10.001
10
ChakrabortyS.AkhterS.RequenaJ. R.BasuS. (2015). Probing the conformational dynamics of the bioactive peptide TLQP-21 in solution: a molecular dynamics study.Chem. Biol. Drug Des.86938–944. 10.1111/cbdd.12541
11
ChenY. C.PristeraA.AyubM.SwanwickR. S.KaruK.HamadaY.et al (2013). Identification of a receptor for neuropeptide VGF and its role in neuropathic pain.J. Biol. Chem.28834638–34646. 10.1074/jbc.M113.510917
12
ChernyakB. V. (1997). Cyclosporin A-sensitive release of Ca2+ from mitochondria in intact thymocytes.FEBS Lett.418131–134. 10.1016/S0014-5793(97)01361-6
13
ClaphamD. E. (2007). Calcium signaling.Cell1311047–1058. 10.1016/j.cell.2007.11.028
14
CoccoC.D’AmatoF.NoliB.LeddaA.BranciaC.BongioanniP.et al (2010). Distribution of VGF peptides in the human cortex and their selective changes in Parkinson’s and Alzheimer’s diseases.J. Anat.217683–693. 10.1111/j.1469-7580.2010.01309.x
15
FairbanksC. A.PetersonC. D.SpeltzR. H.RiedlM. S.KittoK. F.DykstraJ. A.et al (2014). The VGF-derived peptide TLQP-21 contributes to inflammatory and nerve injury-induced hypersensitivity.Pain1551229–1237. 10.1016/j.pain.2014.03.012
16
FengD. D.ZhaoY. F.LuoZ. Q.KeatingD. J.ChenC. (2008). Linoleic acid induces Ca2+-induced inactivation of voltage-dependent Ca2+ currents in rat pancreatic beta-cells.J. Endocrinol.196377–384. 10.1677/JOE-07-0426
17
FerriG. L.GaudioR. M.CossuM.RinaldiA. M.PolakJ. M.BergerP.et al (1995). The “VGF” protein in rat adenohypophysis: sex differences and changes during the estrous cycle and after gonadectomy.Endocrinology1362244–2251.
18
HannedoucheS.BeckV.Leighton-DaviesJ.BeibelM.RomaG.OakeleyE. J.et al (2013). Identification of the C3a receptor (C3AR1) as the target of the VGF-derived peptide TLQP-21 in rodent cells.J. Biol. Chem.28827434–27443. 10.1074/jbc.M113.497214
19
HewavitharanaT.DengX.SoboloffJ.GillD. L. (2007). Role of STIM and Orai proteins in the store-operated calcium signaling pathway.Cell Calcium42173–182. 10.1016/j.ceca.2007.03.009
20
IshikawaJ.OhgaK.YoshinoT.TakezawaR.IchikawaA.KubotaH.et al (2003). A pyrazole derivative, YM-58483, potently inhibits store-operated sustained Ca2+ influx and IL-2 production in T lymphocytes.J. Immunol.1704441–4449. 10.4049/jimmunol.170.9.4441
21
LeviA.EldridgeJ. D.PatersonB. M. (1985). Molecular cloning of a gene sequence regulated by nerve growth factor.Science229393–395. 10.1126/science.3839317
22
LeviA.FerriG. L.WatsonE.PossentiR.SaltonS. R. (2004). Processing, distribution, and function of VGF, a neuronal and endocrine peptide precursor.Cell Mol. Neurobiol.24517–533. 10.1023/B:CEMN.0000023627.79947.22
23
LiJ. H.ZhaoS. T.WuC. Y.CaoX.PengM. R.LiS. J.et al (2013). Store-operated Ca2+ channels blockers inhibit lipopolysaccharide induced astrocyte activation.Neurochem. Res.382216–2226. 10.1007/s11064-013-1130-0
24
LiantonioA.GiannuzziV.CipponeV.CamerinoG. M.PiernoS.CamerinoD. C. (2007). Fluvastatin and atorvastatin affect calcium homeostasis of rat skeletal muscle fibers in vivo and in vitro by impairing the sarcoplasmic reticulum/mitochondria Ca2+-release system.J. Pharmacol. Exp. Ther.321626–634. 10.1124/jpet.106.118331
25
LiouJ.KimM. L.HeoW. D.JonesJ. T.MyersJ. W.FerrellJ. E.Jr.et al (2005). STIM is a Ca2+ sensor essential for Ca2+-store-depletion-triggered Ca2+ influx.Curr. Biol.151235–1241. 10.1016/j.cub.2005.05.055
26
MacmillanD.McCarronJ. G. (2010). The phospholipase C inhibitor U-73122 inhibits Ca(2+) release from the intracellular sarcoplasmic reticulum Ca(2+) store by inhibiting Ca(2+) pumps in smooth muscle.Br. J. Pharmacol.1601295–1301. 10.1111/j.1476-5381.2010.00771.x
27
MuccioliG.GheC.GhigoM. C.PapottiM.ArvatE.BoghenM. F.et al (1998). Specific receptors for synthetic GH secretagogues in the human brain and pituitary gland.J. Endocrinol.15799–106. 10.1677/joe.0.1570099
28
MuccioliG.PapottiM.LocatelliV.GhigoE.DeghenghiR. (2001). Binding of 125I-labeled ghrelin to membranes from human hypothalamus and pituitary gland.J. Endocrinol. Invest.24RC7–RC9. 10.1007/bf03343831
29
NadeauS. I.LandryJ. (2007). Mechanisms of activation and regulation of the heat shock-sensitive signaling pathways.Adv. Exp. Med. Biol.594100–113. 10.1007/978-0-387-39975-1_10
30
NoliB.BranciaC.D’AmatoF.FerriG. L.CoccoC. (2014). VGF changes during the estrous cycle: a novel endocrine role for TLQP peptides?PLoS ONE9:e108456. 10.1371/journal.pone.0108456
31
PetrocchiP.QuaresimaS.MongiardiM. P.SeveriniC.PossentiR. (2010). Activation of kinase phosphorylation by heat-shift and mild heat-shock.Cell Biol. Int. Rep.17:e00002. 10.1042/CBR20100002
32
PossentiR.MuccioliG.PetrocchiP.CeroC.CabassiA.VulchanovaL.et al (2012). Characterization of a novel peripheral pro-lipolytic mechanism in mice: role of VGF-derived peptide TLQP-21.Biochem. J.441511–522. 10.1042/BJ20111165
33
RazzoliM.BoE.PascucciT.PavoneF.D’AmatoF. R.CeroC.et al (2012). Implication of the VGF-derived peptide TLQP-21 in mouse acute and chronic stress responses.Behav. Brain Res.229333–339. 10.1016/j.bbr.2012.01.038
34
RizziR.BartolomucciA.MolesA.D’AmatoF.SacerdoteP.LeviA.et al (2008). The VGF-derived peptide TLQP-21: a new modulatory peptide for inflammatory pain.Neurosci. Lett.441129–133. 10.1016/j.neulet.2008.06.018
35
RoosJ.DiGregorioP. J.YerominA. V.OhlsenK.LioudynoM.ZhangS.et al (2005). STIM1, an essential and conserved component of store-operated Ca2+ channel function.J. Cell Biol.169435–445. 10.1083/jcb.200502019
36
RuetschiU.ZetterbergH.PodustV. N.GottfriesJ.LiS.Hviid SimonsenA.et al (2005). Identification of CSF biomarkers for frontotemporal dementia using SELDI-TOF.Exp. Neurol.196273–281. 10.1016/j.expneurol.2005.08.002
37
SaltonS. R.FerriG. L.HahmS.SnyderS. E.WilsonA. J.PossentiR.et al (2000). VGF: a novel role for this neuronal and neuroendocrine polypeptide in the regulation of energy balance.Front. Neuroendocrinol.21:199–219. 10.1006/frne.2000.0199
38
SeveriniC.CiottiM. T.BiondiniL.QuaresimaS.RinaldiA. M.LeviA.et al (2008). TLQP-21, a neuroendocrine VGF-derived peptide, prevents cerebellar granule cells death induced by serum and potassium deprivation.J. Neurochem.104534–544. 10.1111/j.1471-4159.2007.05068.x
39
ShoichetB. K.KobilkaB. K. (2012). Structure-based drug screening for G-protein-coupled receptors.Trends Pharmacol. Sci.33268–272. 10.1016/j.tips.2012.03.007
40
SoboloffJ.RothbergB. S.MadeshM.GillD. L. (2012). STIM proteins: dynamic calcium signal transducers.Nat. Rev. Mol. Cell Biol.13549–565. 10.1038/nrm3414
41
StephensS. B.SchislerJ. C.HohmeierH. E.AnJ.SunA. Y.PittG. S.et al (2012). A VGF-derived peptide attenuates development of type 2 diabetes via enhancement of islet beta-cell survival and function.Cell Metab.1633–43. 10.1016/j.cmet.2012.05.011
42
ThastrupO.DawsonA. P.ScharffO.FoderB.CullenP. J.DrobakB. K.et al (1989). Thapsigargin, a novel molecular probe for studying intracellular calcium release and storage.Agents Actions2717–23. 10.1007/BF02222186
43
TraniE.GiorgiA.CanuN.AmadoroG.RinaldiA. M.HalbanP. A.et al (2002). Isolation and characterization of VGF peptides in rat brain. Role of PC1/3 and PC2 in the maturation of VGF precursor.J. Neurochem.81565–574. 10.1046/j.1471-4159.2002.00842.x
44
VerkhratskyA. J.PetersenO. H. (1998). Neuronal calcium stores.Cell Calcium24333–343. 10.1016/S0143-4160(98)90057-4
Summary
Keywords
TLQP-21, VGF, calcium, SOCE, STIM-1, receptor, CHO, HFHH-10
Citation
Molteni L, Rizzi L, Bresciani E, Possenti R, Petrocchi Passeri P, Ghè C, Muccioli G, Fehrentz J-A, Verdié P, Martinez J, Omeljaniuk RJ, Biagini G, Binda A, Rivolta I, Locatelli V and Torsello A (2017) Pharmacological and Biochemical Characterization of TLQP-21 Activation of a Binding Site on CHO Cells. Front. Pharmacol. 8:167. doi: 10.3389/fphar.2017.00167
Received
21 December 2016
Accepted
14 March 2017
Published
30 March 2017
Volume
8 - 2017
Edited by
Eero Vasar, University of Tartu, Estonia
Reviewed by
Víctor M. Arce, Universidade de Santiago de Compostela, Spain; Jaanus Harro, University of Tartu, Estonia; Andrew Harkin, Trinity College, Dublin, Ireland
Updates
Copyright
© 2017 Molteni, Rizzi, Bresciani, Possenti, Petrocchi Passeri, Ghè, Muccioli, Fehrentz, Verdié, Martinez, Omeljaniuk, Biagini, Binda, Rivolta, Locatelli and Torsello.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Antonio Torsello, antonio.torsello@unimib.it
This article was submitted to Neuropharmacology, a section of the journal Frontiers in Pharmacology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.